Clinically validated to predict CRC recurrence.
COSMOS-CRC-01: 1,900+ TISSUE-FREE SAMPLES FROM 300+ PATIENTS WITH CRC
# In stage II or higher colon cancer. Percentage is representative of longitudinal sensitivity.
References: 1. Nakamura Y. Tsukada Y. Matsuhashi N, et al. Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay. Clin Cancer Res. 2024. 2. Benson AB. Venook AP. Adam M. et al. Guidelines® Insights: Colon Cancer. Version 1.2025, Clinical practice guidelines in oncology. Accessed Oct 24, 2025.
Clinically validated to predict CRC recurrence.
COSMOS-CRC-01: 1,900+ TISSUE-FREE SAMPLES FROM 300+ PATIENTS WITH CRC
# In stage II or higher colon cancer. Percentage is representative of longitudinal sensitivity.